Notice Regarding Recognition of Non-Operating Income in the Company's Standalone Financial Results under Japanese GAAP | Sumitomo Pharma Co.,Ltd. (4506) timely disclosure

Worth reading

33Immaterial

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

48340

¥ million

Wording

Definitive

How definitive the wording is.

Recognition of non-operating income in the Company's standalone financial results under Japanese GAAP

Subject Entity

Sumitomo Pharma Co.,Ltd.; Sumitomo Pharma Switzerland GmbH (consolidated subsidiary)

This disclosure03/25/2026

Cause

Sumitomo Pharma Switzerland GmbH decided to pay a dividend.

Amount of Impact on Business Performance

¥48,340 million (interest and dividend income, recognized as non-operating income; eliminated in the consolidated financial results)

Accounting period in which recognized

Standalone financial results for the fiscal year ending March 2026 (1 April 2025 to 31 March 2026)

Outlook

Dividend income will be recognized in the standalone financial results for the fiscal year ending March 2026. It will be eliminated in the consolidated financial results and will have no impact on consolidated profit or loss.

Event that occurred
Item	Details
Event name	Recognition of non-operating income in the Company's standalone financial results under Japanese GAAP
Subject Entity	Sumitomo Pharma Co.,Ltd.; Sumitomo Pharma Switzerland GmbH (consolidated subsidiary)
Cause	Sumitomo Pharma Switzerland GmbH decided to pay a dividend.
Amount of Impact on Business Performance	¥48,340 million (interest and dividend income, recognized as non-operating income; eliminated in the consolidated financial results)
Accounting period in which recognized	Standalone financial results for the fiscal year ending March 2026 (1 April 2025 to 31 March 2026)
Outlook	Dividend income will be recognized in the standalone financial results for the fiscal year ending March 2026. It will be eliminated in the consolidated financial results and will have no impact on consolidated profit or loss.

Items this document does not state (19)

Date of occurrenceDate recognized / date notice receivedTarget Locations / ProductsImpact on Earnings ForecastType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Sumitomo Pharma Switzerland GmbH, a consolidated subsidiary, decided to pay a dividend.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.